世界の全身性強皮症治療薬市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Systemic Scleroderma Drugs Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-6029 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、98ページ • 納品方法：Eメール（納期：3日） • 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥585,000 (USD3,900)	▷ お問い合わせ
Multi User	￥877,500 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査レポートでは、全身性強皮症治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（免疫抑制剤、ホスホジエステラーゼ5阻害剤-PHA、エンドセリン受容体拮抗薬、プロスタサイクリン類似体、カルシウムチャネル遮断薬、その他）、用途別市場規模（病院、診療所、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・全身性強皮症治療薬の市場動向 ・企業の競争状況、市場シェア ・全身性強皮症治療薬の種類別市場規模と予測2016-2027（免疫抑制剤、ホスホジエステラーゼ5阻害剤-PHA、エンドセリン受容体拮抗薬、プロスタサイクリン類似体、カルシウムチャネル遮断薬、その他） ・全身性強皮症治療薬の用途別市場規模と予測2016-2027（病院、診療所、その他） ・全身性強皮症治療薬の北米市場規模2016-2027（アメリカ、カナダ） ・全身性強皮症治療薬の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・全身性強皮症治療薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・全身性強皮症治療薬の中南米市場規模2016-2027（メキシコ、ブラジル） ・全身性強皮症治療薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Boehringer Ingelheim International GmbH、Gilead Sciences Inc.、GlaxoSmithKline plc、Novartis AG、Pfizer Inc.、Bayer AG） ・結論

Systemic scleroderma is an autoimmune disorder that affects the skin and internal organs . It is characterized by the buildup of scar tissue (fibrosis) in the skin and other organs. The fibrosis is caused by the body’s production of too much collagen, which normally strengthens and supports connective tissues.

Market Analysis and Insights: Global Systemic Scleroderma Drugs Market
The global Systemic Scleroderma Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Systemic Scleroderma Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Systemic Scleroderma Drugs market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Systemic Scleroderma Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Systemic Scleroderma Drugs market.

Global Systemic Scleroderma Drugs Scope and Market Size
Systemic Scleroderma Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Systemic Scleroderma Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Immunosuppressors
Phosphodiesterase 5 inhibitors – PHA
Endothelin Receptor Antagonists
Prostacyclin Analogues
Calcium Channel Blockers
Others

Segment by Application
Hospital
Clinics
Others

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Boehringer Ingelheim International GmbH
Gilead Sciences Inc.
GlaxoSmithKline plc
Novartis AG
Pfizer Inc.
Bayer AG

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Systemic Scleroderma Drugs Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Immunosuppressors
1.2.3 Phosphodiesterase 5 inhibitors – PHA
1.2.4 Endothelin Receptor Antagonists
1.2.5 Prostacyclin Analogues
1.2.6 Calcium Channel Blockers
1.2.7 Others
1.3 Market by Application
1.3.1 Global Systemic Scleroderma Drugs Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Systemic Scleroderma Drugs Market Perspective (2016-2027)
2.2 Systemic Scleroderma Drugs Growth Trends by Regions
2.2.1 Systemic Scleroderma Drugs Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Systemic Scleroderma Drugs Historic Market Share by Regions (2016-2021)
2.2.3 Systemic Scleroderma Drugs Forecasted Market Size by Regions (2022-2027)
2.3 Systemic Scleroderma Drugs Industry Dynamic
2.3.1 Systemic Scleroderma Drugs Market Trends
2.3.2 Systemic Scleroderma Drugs Market Drivers
2.3.3 Systemic Scleroderma Drugs Market Challenges
2.3.4 Systemic Scleroderma Drugs Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Systemic Scleroderma Drugs Players by Revenue
3.1.1 Global Top Systemic Scleroderma Drugs Players by Revenue (2016-2021)
3.1.2 Global Systemic Scleroderma Drugs Revenue Market Share by Players (2016-2021)
3.2 Global Systemic Scleroderma Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Systemic Scleroderma Drugs Revenue
3.4 Global Systemic Scleroderma Drugs Market Concentration Ratio
3.4.1 Global Systemic Scleroderma Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Systemic Scleroderma Drugs Revenue in 2020
3.5 Systemic Scleroderma Drugs Key Players Head office and Area Served
3.6 Key Players Systemic Scleroderma Drugs Product Solution and Service
3.7 Date of Enter into Systemic Scleroderma Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Systemic Scleroderma Drugs Breakdown Data by Type
4.1 Global Systemic Scleroderma Drugs Historic Market Size by Type (2016-2021)
4.2 Global Systemic Scleroderma Drugs Forecasted Market Size by Type (2022-2027)

5 Systemic Scleroderma Drugs Breakdown Data by Application
5.1 Global Systemic Scleroderma Drugs Historic Market Size by Application (2016-2021)
5.2 Global Systemic Scleroderma Drugs Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Systemic Scleroderma Drugs Market Size (2016-2027)
6.2 North America Systemic Scleroderma Drugs Market Size by Type
6.2.1 North America Systemic Scleroderma Drugs Market Size by Type (2016-2021)
6.2.2 North America Systemic Scleroderma Drugs Market Size by Type (2022-2027)
6.2.3 North America Systemic Scleroderma Drugs Market Size by Type (2016-2027)
6.3 North America Systemic Scleroderma Drugs Market Size by Application
6.3.1 North America Systemic Scleroderma Drugs Market Size by Application (2016-2021)
6.3.2 North America Systemic Scleroderma Drugs Market Size by Application (2022-2027)
6.3.3 North America Systemic Scleroderma Drugs Market Size by Application (2016-2027)
6.4 North America Systemic Scleroderma Drugs Market Size by Country
6.4.1 North America Systemic Scleroderma Drugs Market Size by Country (2016-2021)
6.4.2 North America Systemic Scleroderma Drugs Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Systemic Scleroderma Drugs Market Size (2016-2027)
7.2 Europe Systemic Scleroderma Drugs Market Size by Type
7.2.1 Europe Systemic Scleroderma Drugs Market Size by Type (2016-2021)
7.2.2 Europe Systemic Scleroderma Drugs Market Size by Type (2022-2027)
7.2.3 Europe Systemic Scleroderma Drugs Market Size by Type (2016-2027)
7.3 Europe Systemic Scleroderma Drugs Market Size by Application
7.3.1 Europe Systemic Scleroderma Drugs Market Size by Application (2016-2021)
7.3.2 Europe Systemic Scleroderma Drugs Market Size by Application (2022-2027)
7.3.3 Europe Systemic Scleroderma Drugs Market Size by Application (2016-2027)
7.4 Europe Systemic Scleroderma Drugs Market Size by Country
7.4.1 Europe Systemic Scleroderma Drugs Market Size by Country (2016-2021)
7.4.2 Europe Systemic Scleroderma Drugs Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Systemic Scleroderma Drugs Market Size (2016-2027)
8.2 Asia-Pacific Systemic Scleroderma Drugs Market Size by Type
8.2.1 Asia-Pacific Systemic Scleroderma Drugs Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Systemic Scleroderma Drugs Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Systemic Scleroderma Drugs Market Size by Type (2016-2027)
8.3 Asia-Pacific Systemic Scleroderma Drugs Market Size by Application
8.3.1 Asia-Pacific Systemic Scleroderma Drugs Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Systemic Scleroderma Drugs Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Systemic Scleroderma Drugs Market Size by Application (2016-2027)
8.4 Asia-Pacific Systemic Scleroderma Drugs Market Size by Region
8.4.1 Asia-Pacific Systemic Scleroderma Drugs Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Systemic Scleroderma Drugs Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Systemic Scleroderma Drugs Market Size (2016-2027)
9.2 Latin America Systemic Scleroderma Drugs Market Size by Type
9.2.1 Latin America Systemic Scleroderma Drugs Market Size by Type (2016-2021)
9.2.2 Latin America Systemic Scleroderma Drugs Market Size by Type (2022-2027)
9.2.3 Latin America Systemic Scleroderma Drugs Market Size by Type (2016-2027)
9.3 Latin America Systemic Scleroderma Drugs Market Size by Application
9.3.1 Latin America Systemic Scleroderma Drugs Market Size by Application (2016-2021)
9.3.2 Latin America Systemic Scleroderma Drugs Market Size by Application (2022-2027)
9.3.3 Latin America Systemic Scleroderma Drugs Market Size by Application (2016-2027)
9.4 Latin America Systemic Scleroderma Drugs Market Size by Country
9.4.1 Latin America Systemic Scleroderma Drugs Market Size by Country (2016-2021)
9.4.2 Latin America Systemic Scleroderma Drugs Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Systemic Scleroderma Drugs Market Size (2016-2027)
10.2 Middle East & Africa Systemic Scleroderma Drugs Market Size by Type
10.2.1 Middle East & Africa Systemic Scleroderma Drugs Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Systemic Scleroderma Drugs Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Systemic Scleroderma Drugs Market Size by Type (2016-2027)
10.3 Middle East & Africa Systemic Scleroderma Drugs Market Size by Application
10.3.1 Middle East & Africa Systemic Scleroderma Drugs Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Systemic Scleroderma Drugs Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Systemic Scleroderma Drugs Market Size by Application (2016-2027)
10.4 Middle East & Africa Systemic Scleroderma Drugs Market Size by Country
10.4.1 Middle East & Africa Systemic Scleroderma Drugs Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Systemic Scleroderma Drugs Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Boehringer Ingelheim International GmbH
11.1.1 Boehringer Ingelheim International GmbH Company Details
11.1.2 Boehringer Ingelheim International GmbH Business Overview
11.1.3 Boehringer Ingelheim International GmbH Systemic Scleroderma Drugs Introduction
11.1.4 Boehringer Ingelheim International GmbH Revenue in Systemic Scleroderma Drugs Business (2016-2021)
11.1.5 Boehringer Ingelheim International GmbH Recent Development
11.2 Gilead Sciences Inc.
11.2.1 Gilead Sciences Inc. Company Details
11.2.2 Gilead Sciences Inc. Business Overview
11.2.3 Gilead Sciences Inc. Systemic Scleroderma Drugs Introduction
11.2.4 Gilead Sciences Inc. Revenue in Systemic Scleroderma Drugs Business (2016-2021)
11.2.5 Gilead Sciences Inc. Recent Development
11.3 GlaxoSmithKline plc
11.3.1 GlaxoSmithKline plc Company Details
11.3.2 GlaxoSmithKline plc Business Overview
11.3.3 GlaxoSmithKline plc Systemic Scleroderma Drugs Introduction
11.3.4 GlaxoSmithKline plc Revenue in Systemic Scleroderma Drugs Business (2016-2021)
11.3.5 GlaxoSmithKline plc Recent Development
11.4 Novartis AG
11.4.1 Novartis AG Company Details
11.4.2 Novartis AG Business Overview
11.4.3 Novartis AG Systemic Scleroderma Drugs Introduction
11.4.4 Novartis AG Revenue in Systemic Scleroderma Drugs Business (2016-2021)
11.4.5 Novartis AG Recent Development
11.5 Pfizer Inc.
11.5.1 Pfizer Inc. Company Details
11.5.2 Pfizer Inc. Business Overview
11.5.3 Pfizer Inc. Systemic Scleroderma Drugs Introduction
11.5.4 Pfizer Inc. Revenue in Systemic Scleroderma Drugs Business (2016-2021)
11.5.5 Pfizer Inc. Recent Development
11.6 Bayer AG
11.6.1 Bayer AG Company Details
11.6.2 Bayer AG Business Overview
11.6.3 Bayer AG Systemic Scleroderma Drugs Introduction
11.6.4 Bayer AG Revenue in Systemic Scleroderma Drugs Business (2016-2021)
11.6.5 Bayer AG Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Systemic Scleroderma Drugs Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Immunosuppressors
Table 3. Key Players of Phosphodiesterase 5 inhibitors - PHA
Table 4. Key Players of Endothelin Receptor Antagonists
Table 5. Key Players of Prostacyclin Analogues
Table 6. Key Players of Calcium Channel Blockers
Table 7. Key Players of Others
Table 8. Global Systemic Scleroderma Drugs Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 9. Global Systemic Scleroderma Drugs Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 10. Global Systemic Scleroderma Drugs Market Size by Regions (2016-2021) & (US$ Million)
Table 11. Global Systemic Scleroderma Drugs Market Share by Regions (2016-2021)
Table 12. Global Systemic Scleroderma Drugs Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 13. Global Systemic Scleroderma Drugs Market Share by Regions (2022-2027)
Table 14. Systemic Scleroderma Drugs Market Trends
Table 15. Systemic Scleroderma Drugs Market Drivers
Table 16. Systemic Scleroderma Drugs Market Challenges
Table 17. Systemic Scleroderma Drugs Market Restraints
Table 18. Global Systemic Scleroderma Drugs Revenue by Players (2016-2021) & (US$ Million)
Table 19. Global Systemic Scleroderma Drugs Market Share by Players (2016-2021)
Table 20. Global Top Systemic Scleroderma Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Systemic Scleroderma Drugs as of 2020)
Table 21. Ranking of Global Top Systemic Scleroderma Drugs Companies by Revenue (US$ Million) in 2020
Table 22. Global 5 Largest Players Market Share by Systemic Scleroderma Drugs Revenue (CR5 and HHI) & (2016-2021)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Systemic Scleroderma Drugs Product Solution and Service
Table 25. Date of Enter into Systemic Scleroderma Drugs Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Systemic Scleroderma Drugs Market Size by Type (2016-2021) (US$ Million)
Table 28. Global Systemic Scleroderma Drugs Revenue Market Share by Type (2016-2021)
Table 29. Global Systemic Scleroderma Drugs Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 30. Global Systemic Scleroderma Drugs Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 31. Global Systemic Scleroderma Drugs Market Size Share by Application (2016-2021) & (US$ Million)
Table 32. Global Systemic Scleroderma Drugs Revenue Market Share by Application (2016-2021)
Table 33. Global Systemic Scleroderma Drugs Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 34. Global Systemic Scleroderma Drugs Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 35. North America Systemic Scleroderma Drugs Market Size by Type (2016-2021) (US$ Million)
Table 36. North America Systemic Scleroderma Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 37. North America Systemic Scleroderma Drugs Market Size by Application (2016-2021) (US$ Million)
Table 38. North America Systemic Scleroderma Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 39. North America Systemic Scleroderma Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 40. North America Systemic Scleroderma Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 41. Europe Systemic Scleroderma Drugs Market Size by Type (2016-2021) (US$ Million)
Table 42. Europe Systemic Scleroderma Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 43. Europe Systemic Scleroderma Drugs Market Size by Application (2016-2021) (US$ Million)
Table 44. Europe Systemic Scleroderma Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 45. Europe Systemic Scleroderma Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 46. Europe Systemic Scleroderma Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Systemic Scleroderma Drugs Market Size by Type (2016-2021) (US$ Million)
Table 48. Asia-Pacific Systemic Scleroderma Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Systemic Scleroderma Drugs Market Size by Application (2016-2021) (US$ Million)
Table 50. Asia-Pacific Systemic Scleroderma Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 51. Asia-Pacific Systemic Scleroderma Drugs Market Size by Region (2016-2021) & (US$ Million)
Table 52. Asia-Pacific Systemic Scleroderma Drugs Market Size by Region (2022-2027) & (US$ Million)
Table 53. Latin America Systemic Scleroderma Drugs Market Size by Type (2016-2021) (US$ Million)
Table 54. Latin America Systemic Scleroderma Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 55. Latin America Systemic Scleroderma Drugs Market Size by Application (2016-2021) (US$ Million)
Table 56. Latin America Systemic Scleroderma Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 57. Latin America Systemic Scleroderma Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 58. Latin America Systemic Scleroderma Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Systemic Scleroderma Drugs Market Size by Type (2016-2021) (US$ Million)
Table 60. Middle East & Africa Systemic Scleroderma Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Systemic Scleroderma Drugs Market Size by Application (2016-2021) (US$ Million)
Table 62. Middle East & Africa Systemic Scleroderma Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 63. Middle East & Africa Systemic Scleroderma Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 64. Middle East & Africa Systemic Scleroderma Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 65. Boehringer Ingelheim International GmbH Company Details
Table 66. Boehringer Ingelheim International GmbH Business Overview
Table 67. Boehringer Ingelheim International GmbH Systemic Scleroderma Drugs Product
Table 68. Boehringer Ingelheim International GmbH Revenue in Systemic Scleroderma Drugs Business (2016-2021) & (US$ Million)
Table 69. Boehringer Ingelheim International GmbH Recent Development
Table 70. Gilead Sciences Inc. Company Details
Table 71. Gilead Sciences Inc. Business Overview
Table 72. Gilead Sciences Inc. Systemic Scleroderma Drugs Product
Table 73. Gilead Sciences Inc. Revenue in Systemic Scleroderma Drugs Business (2016-2021) & (US$ Million)
Table 74. Gilead Sciences Inc. Recent Development
Table 75. GlaxoSmithKline plc Company Details
Table 76. GlaxoSmithKline plc Business Overview
Table 77. GlaxoSmithKline plc Systemic Scleroderma Drugs Product
Table 78. GlaxoSmithKline plc Revenue in Systemic Scleroderma Drugs Business (2016-2021) & (US$ Million)
Table 79. GlaxoSmithKline plc Recent Development
Table 80. Novartis AG Company Details
Table 81. Novartis AG Business Overview
Table 82. Novartis AG Systemic Scleroderma Drugs Product
Table 83. Novartis AG Revenue in Systemic Scleroderma Drugs Business (2016-2021) & (US$ Million)
Table 84. Novartis AG Recent Development
Table 85. Pfizer Inc. Company Details
Table 86. Pfizer Inc. Business Overview
Table 87. Pfizer Inc. Systemic Scleroderma Drugs Product
Table 88. Pfizer Inc. Revenue in Systemic Scleroderma Drugs Business (2016-2021) & (US$ Million)
Table 89. Pfizer Inc. Recent Development
Table 90. Bayer AG Company Details
Table 91. Bayer AG Business Overview
Table 92. Bayer AG Systemic Scleroderma Drugs Product
Table 93. Bayer AG Revenue in Systemic Scleroderma Drugs Business (2016-2021) & (US$ Million)
Table 94. Bayer AG Recent Development
Table 95. Research Programs/Design for This Report
Table 96. Key Data Information from Secondary Sources
Table 97. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Systemic Scleroderma Drugs Market Share by Type: 2020 VS 2027
Figure 2. Immunosuppressors Features
Figure 3. Phosphodiesterase 5 inhibitors - PHA Features
Figure 4. Endothelin Receptor Antagonists Features
Figure 5. Prostacyclin Analogues Features
Figure 6. Calcium Channel Blockers Features
Figure 7. Others Features
Figure 8. Global Systemic Scleroderma Drugs Market Share by Application: 2020 VS 2027
Figure 9. Hospital Case Studies
Figure 10. Clinics Case Studies
Figure 11. Others Case Studies
Figure 12. Systemic Scleroderma Drugs Report Years Considered
Figure 13. Global Systemic Scleroderma Drugs Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 14. Global Systemic Scleroderma Drugs Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 15. Global Systemic Scleroderma Drugs Market Share by Regions: 2020 VS 2027
Figure 16. Global Systemic Scleroderma Drugs Market Share by Regions (2022-2027)
Figure 17. Global Systemic Scleroderma Drugs Market Share by Players in 2020
Figure 18. Global Top Systemic Scleroderma Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Systemic Scleroderma Drugs as of 2020
Figure 19. The Top 10 and 5 Players Market Share by Systemic Scleroderma Drugs Revenue in 2020
Figure 20. Global Systemic Scleroderma Drugs Revenue Market Share by Type (2016-2021)
Figure 21. Global Systemic Scleroderma Drugs Revenue Market Share by Type (2022-2027)
Figure 22. North America Systemic Scleroderma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. North America Systemic Scleroderma Drugs Market Share by Type (2016-2027)
Figure 24. North America Systemic Scleroderma Drugs Market Share by Application (2016-2027)
Figure 25. North America Systemic Scleroderma Drugs Market Share by Country (2016-2027)
Figure 26. United States Systemic Scleroderma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Canada Systemic Scleroderma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Systemic Scleroderma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. Europe Systemic Scleroderma Drugs Market Share by Type (2016-2027)
Figure 30. Europe Systemic Scleroderma Drugs Market Share by Application (2016-2027)
Figure 31. Europe Systemic Scleroderma Drugs Market Share by Country (2016-2027)
Figure 32. Germany Systemic Scleroderma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. France Systemic Scleroderma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. U.K. Systemic Scleroderma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Italy Systemic Scleroderma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Russia Systemic Scleroderma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Nordic Systemic Scleroderma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Systemic Scleroderma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Asia-Pacific Systemic Scleroderma Drugs Market Share by Type (2016-2027)
Figure 40. Asia-Pacific Systemic Scleroderma Drugs Market Share by Application (2016-2027)
Figure 41. Asia-Pacific Systemic Scleroderma Drugs Market Share by Region (2016-2027)
Figure 42. China Systemic Scleroderma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Japan Systemic Scleroderma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. South Korea Systemic Scleroderma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Southeast Asia Systemic Scleroderma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. India Systemic Scleroderma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Australia Systemic Scleroderma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Systemic Scleroderma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Latin America Systemic Scleroderma Drugs Market Share by Type (2016-2027)
Figure 50. Latin America Systemic Scleroderma Drugs Market Share by Application (2016-2027)
Figure 51. Latin America Systemic Scleroderma Drugs Market Share by Country (2016-2027)
Figure 52. Mexico Systemic Scleroderma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Brazil Systemic Scleroderma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Systemic Scleroderma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Middle East & Africa Systemic Scleroderma Drugs Market Share by Type (2016-2027)
Figure 56. Middle East & Africa Systemic Scleroderma Drugs Market Share by Application (2016-2027)
Figure 57. Middle East & Africa Systemic Scleroderma Drugs Market Share by Country (2016-2027)
Figure 58. Turkey Systemic Scleroderma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Saudi Arabia Systemic Scleroderma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. UAE Systemic Scleroderma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 61. Boehringer Ingelheim International GmbH Revenue Growth Rate in Systemic Scleroderma Drugs Business (2016-2021)
Figure 62. Gilead Sciences Inc. Revenue Growth Rate in Systemic Scleroderma Drugs Business (2016-2021)
Figure 63. GlaxoSmithKline plc Revenue Growth Rate in Systemic Scleroderma Drugs Business (2016-2021)
Figure 64. Novartis AG Revenue Growth Rate in Systemic Scleroderma Drugs Business (2016-2021)
Figure 65. Pfizer Inc. Revenue Growth Rate in Systemic Scleroderma Drugs Business (2016-2021)
Figure 66. Bayer AG Revenue Growth Rate in Systemic Scleroderma Drugs Business (2016-2021)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed

---